LSP Management Group

LSP Management Group is a venture capital firm specializing in investments within the life sciences sector. With a strong presence in both the United States and Europe, the firm leverages its extensive expertise to identify and support innovative companies in healthcare, biotechnology, and related fields. Founded in 1988 and based in Cambridge, Massachusetts, LSP Management Group combines the insights of a dedicated team with a robust network to drive growth and development in the life sciences industry. The firm is committed to fostering advancements that improve patient care and contribute to the overall health landscape.

Christoph Broja

Managing Director

Kevin Hammon

Vice President

Martijn Kleijwegt

Managing Partner

Maximilian Moser Ph.D

Vice President

29 past transactions

HotSpot Therapeutics

Series C in 2021
HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

Evommune

Series A in 2021
Evommune, Inc. is a biotechnology company based in Los Altos, California, that focuses on developing and manufacturing tissue-based medicines aimed at treating inflammatory diseases. Founded in 2020, the company employs a proprietary tissue-based platform to accelerate the discovery of novel therapies, with a particular emphasis on immunology and dermatology. Evommune's approach seeks not only to alleviate the symptoms of inflammatory disorders but also to halt disease progression, thereby improving the quality of life for patients. Its pipeline includes initiatives targeting prevalent inflammatory conditions, with a commitment to advancing patient care by creating best-in-class treatment options. Through innovative strategies, Evommune aims to drive meaningful advancements in the field of inflammatory disease management.

Muna Therapeutics

Series A in 2021
Muna Therapeutics is a biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases, such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying new medicines that preserve cognitive function and enhance resilience against these debilitating conditions, thereby providing individuals affected by neurodegenerative diseases with access to effective treatment options. Through its innovative approach, Muna Therapeutics strives to improve the quality of life for those suffering from these challenging disorders.

Innovative Molecules

Series A in 2021
Innovative Molecules is a drug development company focused on creating treatments for diseases caused by the Herpes simplex virus. The company is advancing its lead product, IM-250, which is a second-generation helicase-primase inhibitor targeting both HSV-1 and HSV-2. This innovative treatment is designed not only to inhibit active viral replication but also to potentially reduce or eliminate the viral reservoir in patients. By doing so, Innovative Molecules aims to enhance the therapeutic options available for managing Herpes simplex-induced diseases, providing a significant advancement in patient care.

NewAmsterdam Pharma Company

Series A in 2021
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for cardio-metabolic diseases. The company aims to enhance patient care for those suffering from metabolic conditions where existing treatments are insufficient or poorly tolerated. Its lead product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor designed to address the shortcomings of current LDL-C lowering therapies. Through its focus on transformative solutions, NewAmsterdam Pharma seeks to make a significant impact in the management of cardio-metabolic diseases.

Lumeon

Series D in 2020
Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

iSTAR Medical

Series C in 2019
iSTAR Medical SA is a Belgian company specializing in the development of innovative ophthalmic implants aimed at treating glaucoma. Founded in 2010 as a spinout of Healionics Corporation, the company has established a strong presence in the market with its flagship product, the STARflo glaucoma implant. This non-degradable, micro-porous drainage system reduces intraocular pressure in patients with open-angle glaucoma by enhancing the eye's natural uveoscleral outflow. iSTAR Medical also offers additional products, including STARflo PLUS and STARflo MINI, which provide surgical therapies for glaucoma. The implants are designed to integrate with surrounding tissue, exhibiting anti-fibrotic and anti-inflammatory properties, thereby minimizing complications and the need for medication. The company operates from its eco-friendly R&D and manufacturing facility in Belgium and distributes its products across various international markets, including Australia, China, France, Hungary, Italy, Poland, and Turkey. iSTAR Medical has received multiple quality certifications, including ISO 13485 and ISO 9001, and achieved CE Mark approval for its devices.

ImCyse

Series B in 2019
ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

Lumeon

Series C in 2018
Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

Aelin Therapeutics

Series A in 2017
Aelin Therapeutics is a Belgian biotherapeutics company established in 2017 and headquartered in Heverlee. It specializes in developing innovative antibiotics and therapeutics through its proprietary Pept-in technology, which utilizes protein aggregation to achieve functional knockdown of target proteins. This platform is designed to address challenging medical conditions, including infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) and other undruggable targets in humans. The company was founded by VIB in collaboration with partner universities, including KU Leuven, VUB, and UGent, and is backed by extensive preclinical proof-of-concept data. Aelin Therapeutics' approach allows for the rational design of novel biotherapeutics, distinguishing itself from traditional therapeutic modalities by targeting intracellular spaces typically inaccessible to small molecules or antibodies. The technology's versatility extends beyond human applications, demonstrating efficacy against bacteria, cancer cells, fungi, viruses, and even plant cells.

Nouscom

Series B in 2017
Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Eloxx

Series C in 2017
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Rainier Therapeutics

Series B in 2017
Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.

Immunic Therapeutics

Series A in 2017
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Luxendo

Series A in 2017
Luxendo specializes in the development and manufacture of advanced light-sheet fluorescence microscopy instruments, specifically Single Plane Illumination Microscopes (SPIM). Originally developed at the European Molecular Biology Laboratory by Lars Hufnagel and his team, the SPIM technology offers a novel approach to bio-imaging by combining optical sectioning with multiple-view imaging. This technique allows for rapid three-dimensional imaging of living specimens, such as spheroids and whole organisms, without the need for sample rotation. The design prioritizes gentle handling, making it suitable for delicate cell cultures and developing embryonic samples. As a result, Luxendo's instruments enable scientists to observe living organisms over extended periods without causing photo damage, thereby enhancing research capabilities in various biological fields.

Ventaleon

Venture Round in 2015
Ventaleon is focused on developing inhaled treatments for viral infections, with its lead therapy being inhaled LASAG, a lysin-salt formulation of acetylsalicylic acid. This therapy has undergone Phase II clinical trials for the treatment of severe influenza, where a proof-of-concept study indicated faster symptom relief compared to standard treatments. Ventaleon is currently preparing to enter a pivotal clinical trial for inhaled LASAG. Founded in 2012 as a spin-off from Activaero, a specialist in aerosol inhalation therapies, the company aims to provide a noninvasive treatment option for influenza, enabling physicians to improve patient outcomes.

Sequana Medical

Series C in 2014
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Argenx

Series B in 2011
Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.

Curetis

Series A in 2011
Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.

Activaero

Series A in 2011
Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.

Syntaxin

Series C in 2010
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Affectis Pharmaceuticals

Series D in 2010
Affectis Pharmaceuticals is a company focused on developing innovative drugs to treat neurodegenerative, neuroinflammatory, psychiatric, and inflammatory disorders. The firm utilizes research findings in the areas of depression, schizophrenia, and inflammation to discover and create new therapeutic options. Through its commitment to addressing these complex diseases, Affectis aims to advance healthcare solutions and improve patient outcomes.

BMEYE

Series B in 2009
BMEYE B.V., based in Amsterdam, Netherlands, is a company focused on non-invasive cardiovascular monitoring through the research and development of advanced medical technologies. The company provides a range of products designed to measure blood pressure and cardiac output, including the Finapres and Portapres, which are continuous finger blood pressure monitors, and the Finometer, a stationary device for brachial pressure and hemodynamic assessments. BMEYE also offers BeatScope software for arterial pressure waveform analysis, Modelflow for aortic flow waveform computation, and devices like Cardiopres and Oxyflow for specialized research and clinical applications. Its Nexfin and ccNexfin products are approved for use in the U.S. and Europe, catering to cardiology, anesthesiology, and critical care environments. BMEYE distributes its innovative monitoring solutions through a network of partners, aiming to enhance cardiovascular care and research globally.

Pasteuria Bioscience

Series B in 2007
Pasteuria Bioscience, Inc., established in 2003 at the University of Florida's Sid Martin Biotechnology Incubator, focuses on developing biological nematicides to combat nematode pests affecting agricultural crops. The company emerged from Entomos, Inc. to commercialize innovative technology for producing nematode control products. Pasteuria has successfully secured over $6 million in venture funding, which has facilitated the advancement of its technology to commercial-scale production and the EPA registration of its first product aimed at controlling sting nematodes in professional turf. This product is anticipated to launch following extensive turf field trials and other commercial development efforts. Additionally, Pasteuria Bioscience is actively expanding its pipeline of products and bolstering its intellectual property portfolio through a robust laboratory development program.

Attune Foods

Series B in 2007
Attune Foods, Inc. is a producer of organic snacks, headquartered in San Francisco, California, with additional operations in Eugene, Oregon. Established in 2006, the company specializes in probiotic wellness bars available in a variety of flavors, including dark chocolate, chocolate crisp, and mint chocolate, among others. In addition to these bars, Attune Foods offers a range of products such as granolas featuring chocolate or yogurt chips, muesli, cereal products, and graham crackers. The company's focus is on providing customized healthy food options to support consumer wellness.

Efficas

Series B in 2006
Efficas, Inc., based in Boulder, Colorado, is a health science and technology company that specializes in the research, development, and commercialization of products aimed at nutritional management of the immune system for both humans and pets. Founded in 2003, the company offers EFFICAS CARE, a berry-flavored non-prescription medical food designed to assist in the dietary management of asthma and related allergies. Efficas focuses on creating effective solutions that work with the body's natural systems, providing safe and significant health benefits to patients suffering from asthma and allergic conditions.

U3 Pharma

Venture Round in 2006
U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in targeted cancer drug development. Established in July 2001, the company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Professor Axel Ullrich. Since May 2008 U3 Pharma belongs to DAIICHI Sankyo Co. Ltd., one of the top 20 leading pharmaceutical companies worldwide and no. 3 in Japan. Being part of this global environment, U3 Pharma is striving to provide patients around the world with innovative antibody-based therapeutics.

KuDOS Pharmaceuticals

Venture Round in 2006
KuDOS Pharmaceuticals Ltd is a pharmaceutical research firm focused on the discovery and development of drugs targeting cancer treatment. The company utilizes the science of DNA damage sensing, signaling, and repair to create small molecule drugs that specifically inhibit the repair processes in cancer cells. This innovative approach aims to enhance the effectiveness of existing radiotherapy and chemotherapy, ultimately improving cancer management and outcomes for patients. By addressing critical medical needs in oncology, KuDOS Pharmaceuticals strives to contribute to advancements in cancer therapies.

Hybrigenics

Venture Round in 2002
Hybrigenics Pharma is a bio-pharmaceutical company specializing in researching and developing new targets and therapies for cancer treatment. Their focus lies in studying Deubiquitinating Enzymes (DUBs) and the potential of patented DUB inhibitors in combating different cancer indications. Notably, the company has ceased the development of inecalcitol, a vitamin D receptor agonist.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.